These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8467286)

  • 21. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial.
    Legros M; Fleury J; Bay JO; Choufi B; Basile M; Condat P; Glenat C; Communal Y; Tavernier F; Bons JM; Chollet P; Plagne R; Chassagne J
    Bone Marrow Transplant; 1997 Feb; 19(3):209-13. PubMed ID: 9028547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.
    Nemunaitis JJ; Singer JW; Sanders JE
    Bone Marrow Transplant; 1991; 7 Suppl 3():24-7. PubMed ID: 1855082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant.
    Vela-Ojeda J; Tripp-Villanueva F; Sanchez-Cortés E; Ayala-Sanchez M; García-Ruiz Esparza MA; Rosas-Cabral A; Gonzalez-Llaven J
    Bone Marrow Transplant; 1999 Dec; 24(12):1307-10. PubMed ID: 10627639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies.
    Richard C; Alsar MJ; Calavia J; Bello-Fernandez C; Baro J; Loyola I; Rios R; Cuadrado MA; Gonzalez-Pardo C; Iriondo A
    Bone Marrow Transplant; 1993 Jun; 11(6):473-8. PubMed ID: 8334429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
    Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
    Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
    Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
    Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation.
    Gupta P; Tiley C; Powles R; Treleaven J; Millar J; Catalano J
    Bone Marrow Transplant; 1992 Jun; 9(6):491-3. PubMed ID: 1628135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
    Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
    Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
    Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
    J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole.
    Imrie KR; Prince HM; Couture F; Brandwein JM; Keating A
    Bone Marrow Transplant; 1995 Feb; 15(2):267-70. PubMed ID: 7773216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
    Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
    Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.